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Some	 histamine	 H1 receptor (H1R) antagonists induce adverse sedative reactions 
caused	by	blockade	of	histamine	transmission	 in	the	brain.	Desloratadine	 is	a	sec‐
ond‐generation	antihistamine	for	treatment	of	allergic	disorders.	Its	binding	to	brain	
H1Rs,	which	 is	 the	 basis	 of	 sedative	 property	 of	 antihistamines,	 has	 not	 been	 ex‐
amined	previously	 in	the	human	brain	by	positron	emission	tomography	(PET).	We	
examined	brain	H1R	binding	potential	ratio	(BPR),	H1R occupancy (H1RO),	and	sub‐
jective sleepiness after oral desloratadine administration in comparison to lorata‐
dine.	Eight	healthy	male	volunteers	underwent	PET	imaging	with	[11C]‐doxepin,	a	PET	
tracer for H1Rs,	after	a	single	oral	administration	of	desloratadine	(5	mg),	loratadine	
(10	mg),	or	placebo	in	a	double‐blind	crossover	study.	BPR	and	H1RO in the cerebral 
cortex	were	calculated,	and	plasma	concentrations	of	 loratadine	and	desloratadine	
were	measured.	Subjective	sleepiness	was	quantified	by	the	Line	Analogue	Rating	









doses,	desloratadine	did	not	bind	significantly	to	brain	H1Rs and did not induce any 
significant sedation.









counter	 sleep	 aids.	To	 reduce	 sedative	 adverse	 reactions,	 second‐
generation	antihistamines	such	as	levocetirizine,	fexofenadine,	and	
loratadine have been developed.10,11
The sedative properties of antihistamines are associated with the 
permeability	 of	 the	 blood‐brain	 barrier	 to	 the	 drug	 molecules.11,12 
Brain	 penetration	 of	 drugs	 was	 associated	 with	 several	 complex	
factors	 including	 P‐glycoprotein,	 molecular	 weight,	 pKa	 and	 lipid	
solubility. H1Rs in the central nervous system have an essential 
role	 in	 activating	 the	 cortices	 during	 wakefulness	 and	 arousal.13,14 
Antihistamines	 penetrating	 the	 blood‐brain	 barrier	 are	 able	 to	 oc‐
cupy cortical and subcortical H1Rs,	 resulting	 in	 sedation	 and	 im‐
paired	 psychomotor	 performance.	 Positron	 emission	 tomography	
(PET)	 using	 [11C]‐doxepin	 as	 a	 potent	 H1R	 ligand	 can	 quantify	 the	
brain H1R occupancy (H1RO) of antihistamines in vivo.
9,15 Our previ‐
ous	study	clearly	demonstrated	that	a	first‐generation	antihistamine,	
d‐chlorpheniramine,	 caused	 impairment	 of	 the	 attention	 system	 of	
humans that was positively proportional to H1RO.
16 On the other 
hand,	H1RO	of	most	second‐generation	antihistamines	was	less	than	
20%	and	did	not	cause	sedation.10,17‐20	Several	previous	studies	re‐
ported that H1RO	determined	by	 [
11C]‐doxepin	PET	was	correlated	
with	the	proportional	impairment	ratio,	a	parameter	used	to	evaluate	
the sedative potential of each antihistamine.20‐23	Therefore,	PET	im‐
aging	by	[11C]‐doxepin	is	recommended	by	the	Consensus	Group	on	
New‐Generation	Antihistamines	(CONGA)	as	a	quantitative	method	
to determine the sedative effects of antihistamines.24
Desloratadine,	 {8‐chloro‐6,11‐dihydro‐11‐(4‐piperidinylidene)‐5H 
‐benzo[5,6]cyclohepta[1,2‐b]pyridine,	 CAS	 100643‐71‐8},	 a	 second‐
generation	antihistamine,	is	a	biologically	active	metabolite	of	lorata‐
dine	 formed	by	CYP3A4	and	CYP2D6	 (Figure	1).25 Desloratadine is 
approved for the treatment of allergic rhinitis and chronic idiopathic 
urticaria	around	the	world.	A	number	of	clinical	studies	have	demon‐
strated the therapeutic efficacy of desloratadine in allergic rhinitis. 
Nayak	and	Schenkel	 found	 that	daily	 administration	of	5‐mg	deslo‐
ratadine significantly improved nasal congestion and stiffness in pa‐
tients with intermittent allergic rhinitis compared with placebo.26	A	
multicentre,	 randomised,	 placebo‐controlled,	 double‐blind	 parallel‐
group trial showed that desloratadine rapidly reduced the symptoms 
of perennial allergic rhinitis with minimal adverse events.27	Moreover,	
administration	of	desloratadine	5	mg	once	daily	was	as	effective	as	
fexofenadine	180	mg,28 bilastine 20 mg29 or rupatadine 10 mg30 in 
seasonal allergic rhinitis. Desloratadine also improved symptoms of 
chronic	idiopathic	urticaria	in	a	multicentre,	randomised,	double‐blind	
placebo‐controlled	 study31	 and	 in	 an	 observational	 postmarketing	
surveillance study32 without serious adverse events. Hong et al per‐
formed	 a	 randomised,	 double‐blind,	 active‐controlled	parallel‐group	
pilot	trial	of	64	patients	and	found	that	levocetirizine	was	more	effi‐
cacious	than	desloratadine,	but	desloratadine	had	less	sedative	effect,	
in the treatment of chronic idiopathic urticaria.33 Central adverse re‐
actions,	such	as	somnolence,	decreased	vigilance	and	impairment	of	
cognitive	functions,	were	less	frequent	with	the	use	of	desloratadine	
compared	 with	 a	 first‐generation	 antihistamine,	 diphenhydramine,	
although diphenhydramine resulted in better improvement in aller‐
gic rhinitis symptoms.34,35 Desloratadine did not impair psychomo‐
tor	performance,36	driving	performance,36	and	tasks	associated	with	
flying37	compared	with	diphenhydramine.	Additionally,	desloratadine	
K E Y W O R D S
brain H1	receptor	occupancy,	desloratadine,	positron	emission	tomography
F I G U R E  1   Chemical structures 
of loratadine and desloratadine. 
In vivo formation of desloratadine 
(descarboethoxyloratadine)	is	primarily	
mediated	by	CYP3A4	and	CYP2D6
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was associated with fewer cardiovascular adverse events than earlier 
second‐generation	antihistamines.38 These studies indicate that treat‐
ment of allergic rhinitis and chronic idiopathic urticaria with deslorata‐
dine	is	clinically	efficacious,	safe,	and	well	tolerated,	without	serious	
adverse events in the central nervous and cardiovascular systems.39,40
The binding of desloratadine to brain H1R has not been previ‐
ously	determined	in	humans	by	PET,	although	the	United	Kingdom	
Medicine	 and	 Healthcare	 Products	 Regulatory	 Agency	 in	 2001,	
the	 US	 Food	 and	 Drug	 Administration	 in	 2002,	 and	 the	 Japan	




and	 loratadine	 (10	mg)	by	using	 [11C]‐doxepin	PET	 in	healthy	male	
volunteers and investigated the correlation between these pa‐





This	 study	 was	 approved	 by	 the	 Ethical	 Committee	 on	 Clinical	
Investigation	 at	 Tohoku	 University	 Hospital	 (Sendai,	 Japan)	
and by the institutional review committee of the Cyclotron and 






We	 recruited	 eight	 healthy	male	 Japanese	 volunteers	 (mean	±	 SD	
age,	23.2	±	1.28	years;	mean	±	SD	body	weight,	59.6	±	5.27	kg)	who	
had	 provided	 written	 informed	 consent	 beforehand.	 None	 of	 the	
participants had any clinical history of physical or psychiatric dis‐
ease.	They	were	not	taking	any	medications	likely	to	interfere	with	
the study results and had no abnormal findings on brain magnetic 
resonance	imaging	(MRI).	The	participants	were	required	to	refrain	




We	 performed	 a	 double‐blind,	 randomised,	 placebo‐controlled	
three‐way	 crossover	 PET	 imaging	 study.	 All	 the	 participants	 re‐
ceived	 single	 oral	 administration	 of	 desloratadine	 (5	mg),	 lorata‐
dine	 (10	 mg),	 or	 a	 lactobacillus	 preparation	 (6	 mg)	 as	 placebo.	
Desloratadine and loratadine were administered according to their 
approved	and	recommended	daily	doses	in	Japan.	The	lactobacillus	
preparation was used as a placebo and was not associated with any 
statistically	 significant	 differences	 between	 pre‐	 and	 postadmin‐
istration in previous studies.18,19,41 The drugs were administered 




venously into each participant 90 minutes after oral administration 
(11:00 am),	 at	 a	 time	 close	 to	 Tmax of desloratadine and lorata‐
dine.6,42‐44	Sixty	minutes	after	[11C]‐doxepin	injection,	the	subjects	
were	 positioned	 on	 the	 couch	 of	 the	 PET	 scanner	 (Eminence	
SET‐3000BX;	 Shimadzu,	 Kyoto,	 Japan)	 for	 transmission	 scanning	
(6	minutes)	and	emission	scanning	in	the	three‐dimensional	mode	
for	 15	 minutes	 (70‐85	 minutes	 after	 [11C]‐doxepin	 injection).	 To	
determine	plasma	concentrations	of	desloratadine	and	loratadine,	
venous blood samples were collected from each participant before 
drug	 administration	 and	30,	 60,	 120,	 and	180	minutes	 after	 oral	




2.4 | Radiosynthesis of [11C]‐doxepin and 
PET procedures
[11C]‐Doxepin	 was	 prepared	 by	 [11C]‐methylation	 of	 desmethyl	
doxepin	with	[11C]‐methyl	triflate,	as	described	previously.47,48 The 
radiochemical	 purity	 of	 [11C]‐doxepin	 was	 >99%,	 and	 its	 specific	
radioactivity	 at	 the	 time	 of	 injection	 was	 198	 ±	 67.9	 GBq	 μmol−1 
(5,355	 ±	 1,833	 mCi	 μmol−1). The injected dose and cold mass 
of	 [11C]‐doxepin	 were	 159	 ±	 11.6	 MBq	 (4.30	 ±	 0.314	 mCi)	 and	
2.42	±	2.13	nmol,	respectively.	Each	participant	received	[11C]‐dox‐
epin by intravenous injection 90 minutes after oral administration of 
the drugs (11:00 am).	Sixty	minutes	later	(12:00	am),	transmission	and	
emission	PET	scans	were	performed	using	a	PET	scanner	(Eminence	
SET‐3000BX).	 The	 PET	 scanning	 covered	 the	 entire	 brain	 in	 one	
scan,	 taking	 transmission	 scan	 (6	 minutes)	 for	 scatter	 and	 tissue	





All	brain	PET	 images	were	 reconstructed	after	 correction	 for	 scatter	
and	tissue	attenuation,	and	standardised	uptake	values	were	calculated	




were	 spatially	 normalised	 with	 MRI‐T1	 images	 of	 each	 participant	
using	Statistical	Parametric	Mapping	 (SPM12;	Wellcome	Department	
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of	Imaging	Neuroscience,	London,	UK).50 The MRI scan was obtained 
with	 a	 1.5T	 MR	 scanner	 (Signa	 EXCITE	 HD	 1.5T;	 General	 Electric,	
Milwaukee,	WI)	 at	 the	 Sendai	Medical	 Imaging	Clinic,	 Sendai,	 Japan.	
PNEURO	tool	of	PMOD	software	 (version	3.4,	PMOD	Technologies,	
Zurich,	Switzerland)	was	used	for	the	placement	and	evaluation	of	re‐
gions of interest (ROI) as described previously.17 The automated ana‐
tomical	labeling	(AAL)	atlas	was	applied	to	all	PET	images	to	calculate	
the	mean	uptake	value	of	each	ROI.	Some	AAL	ROIs	were	combined	
into	 the	 following	 seven	ROIs,	 including	 the	 frontal	 cortex,	 temporal	
cortex,	parietal	cortex,	occipital	cortex	and	the	anterior	and	posterior	
cingulate gyrus and cerebellum. The cerebellum was defined as a refer‐
ence region because the previous study confirmed the negligible H1R 
binding in the cerebellum.51	As	a	parameter	for	specific	H1R binding of 
[11C]‐doxepin	in	each	cerebral	cortex	region,	we	calculated	BPR	using	a	














2.6 | Measurement of plasma concentrations of 
desloratadine and loratadine
The plasma concentrations of desloratadine and loratadine were 
measured	by	high‐performance	 liquid	chromatography/tandem	mass	











rate	of	0.5	mL	min−1 and a column temperature of 40ºC. The mobile 
phase	consisted	of	10	mmol	L−1 ammonium formate and a methanol/
acetonitrile	mixture	 (3:2	 v/v).	Detection	of	 desloratadine,	 loratadine	
and internal standard was based on fragmentation of the precursor ion 
(m/z	=	311,	383,	387	to	product	 ion	m/z	=	259,	337,	341	with	colli‐
sion	energy	of	29,	33,	33	eV	for	desloratadine,	loratadine	and	internal	









Differences	 in	changes	 in	subjective	sleepiness	 (the	LARS	and	SSS	
scores)	from	preadministration	among	the	three	groups	were	exam‐
ined	by	two‐way	analysis	of	variance	(ANOVA)	with	the	Bonferroni	




rection. Differences in H1RO between the desloratadine and lorata‐
dine	groups	were	examined	by	a	paired	Student's	t test. The relations 
between	BPR	and	SSS,	H1RO	and	SSS	were	examined	by	Pearson's	
correlation	test.	Statistical	significance	for	each	analysis	was	defined	
as P < 0.05.	Prism	8	(GraphPad	Software,	San	Diego,	CA)	was	used	
to	perform	all	statistical	analyses.	All	imaging	and	statistical	analyses	








(AUC)	 of	 the	 subjective	 sleepiness	 time	 course,	 did	 not	 differ	 sig‐
nificantly	among	the	desloratadine,	loratadine,	and	placebo	groups	
(Figure	2,	right	panels).	These	results	indicate	that	oral	administration	
of desloratadine or loratadine did not induce subjective sleepiness.
3.2 | Plasma concentrations of 
desloratadine and loratadine
Figure	 3	 shows	 the	 time	 courses	 of	 the	 plasma	 concentrations	 of	
each	 drug.	 Loratadine	 concentration	was	 significantly	 higher	 than	
desloratadine	 concentration	 60	 minutes	 after	 oral	 administration	
(two‐way	ANOVA,	F = 4.48;	Bonferroni	P = 0.028).	The	deslorata‐
dine concentration after oral administration of 10 mg loratadine 
was not significantly different from the desloratadine concentration 
after	oral	administration	of	5	mg	desloratadine.
3.3 | Brain distribution of [11C]‐doxepin
The	mean	 [11C]‐doxepin	 BPR	 images	 in	 the	 eight	 participants	 are	
shown	 in	 Figure	 4.	 The	 red	 area	 indicates	 brain	 regions	 where	
BPR	 was	 high.	 The	 desloratadine	 and	 placebo	 groups	 had	 simi‐
lar	 BPRs	 (mean	 ±	 SD	 desloratadine	 vs	 placebo,	 0.546	 ±	 0.084	 vs	
0.584	±	0.059;	one‐way	ANOVA,	F = 8.20;	Bonferroni	P = 0.250),	
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whereas	the	loratadine	group	had	lower	BPR	than	the	placebo	group	
(mean	±	SD	loratadine	vs	placebo,	0.504	±	0.074	vs	0.584	±	0.059;	
one‐way	 ANOVA,	 F = 8.20;	 Bonferroni	 P = 0.002)	 (Figure	 5,	 left	
panel,	and	Table	1).	These	results	suggest	that	loratadine	permeated	
the	blood‐brain	barrier	slightly	and	bound	to	H1R in the cortices to 
some	extent.	On	the	other	hand,	desloratadine	had	minimal	binding	
to brain H1R.
3.4 | ROI‐based comparison of BPR and H1RO
Table	1	shows	the	mean	BPRs	in	the	cortical	regions.	The	BPRs	of	the	
desloratadine group in each region were not significantly different 
from	those	of	the	placebo	group.	The	BPR	of	the	loratadine	group	
was	lower	than	the	BPR	of	the	placebo	group	in	all	regions	except	
the anterior cingulate gyrus (P < 0.05,	one‐way	ANOVA,	Bonferroni's	
multiple	comparisons	test),	indicating	that	loratadine	might	bind	H1R 
throughout	 the	 neocortex	 especially	 in	 the	 parietal	 cortex,	 with	
more	pronounced	binding	in	the	posterior	cingulate	gyrus,	and	inter‐
mediate binding in subcortical structures.
H1RO following oral administration of desloratadine and lorata‐
dine	was	also	calculated	using	placebo	as	baseline	(0%)	(Figure	5	and	
Table 2). The overall H1RO in the brain did not differ significantly 
between	 the	desloratadine	 and	 loratadine	 groups,	 although	H1RO 
tended to be lower in the desloratadine group than in the loratadine 
F I G U R E  2  Subjective	sleepiness	after	oral	administration	of	desloratadine,	loratadine,	and	placebo.	The	upper	left	panel	shows	the	time	
course	of	the	Line	Analogue	Rating	Scale	(LARS)	sleepiness	(two‐way	ANOVA;	F =	0.495,	P > 0.999).	The	upper	right	panel	shows	total	LARS	
sleepiness,	determined	by	the	area	under	the	curve	(AUC)	of	the	left	panel	(one‐way	ANOVA;	F = 1.36,	P = 0.229). The lower left panel 
shows	the	time	course	of	the	Stanford	Sleepiness	Scale	(SSS)	(two‐way	ANOVA;	F = 0.967,	P > 0.999).	The	lower	right	panel	shows	total	SSS,	
determined	by	the	AUC	of	the	left	panel	(one‐way	ANOVA;	F = 0.497,	P = 0.530)
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group	 (mean	 ±	 SD,	 6.47	 ±	 10.5%	 vs	 13.8	 ±	 7.00%;	 paired	 t	 test,	
P = 0.103)	(Figure	5,	right	panel,	and	Table	2).	The	H1RO in each re‐
gion did not differ significantly between the desloratadine and lo‐
ratadine groups (Table 2).
3.5 | Relation between subjective sleepiness, 
plasma drug concentration, and BPR
Subjective	sleepiness	was	not	correlated	with	BPR	or	H1RO in either 
the	desloratadine	or	the	loratadine	group	(Table	3).	The	plasma	con‐
centration	of	loratadine	(AUC,	µg	mL−1 * min) was significantly cor‐
related	with	overall	BPR	(Pearson	correlation	coefficient	R	=	–0.862;	




the drugs. There was a tendency toward a correlation between the 
plasma concentration of loratadine and H1RO,	but	the	relation	was	







vious study reported that clinically observed H1RO by antihistamines 





H1 antagonists including antipsychotics and antidepressants.
54,55 
The H1RO	of	first‐	and	second‐generation	antihistamines	has	been	
measured	 by	 several	 PET	 research	 groups,	 and	 a	 classification	 of	
these drugs has been proposed according to the level of H1RO.
9 
H1RO	was	 defined	 as	 an	 important	 index	 for	 evaluating	 sedating	
property	 at	 CONGA,	 an	 expert	meeting	 sponsored	 by	 the	 British	
Society	 for	 Allergy	 and	Clinical	 Immunology.24	 Antihistamines	 are	




the H1RO	of	 fexofenadine	 (120	mg)	was	minimal	 (−0.1%),	whereas	




(two‐way	ANOVA;	F = 4.48,	Bonferroni	P = 0.0277)






averaged across each drug condition to generate the mean images 
displayed








0.546	±	0.084	vs	0.584	±	0.059).	 It	 is	obvious	 from	Figure	2	 that	
desloratadine	does	not	induce	subjective	sleepiness.	Previous	stud‐
ies indicated that desloratadine does not impair psychomotor and 
driving performance.36,37	 Based	 on	 the	 PET	 classification	 of	 anti‐
histamines	 and	 previous	 evidence,	 desloratadine	 is	 classified	 as	 a	
nonsedating antihistamine at the therapeutic dose.
We	 compared	 the	 measured	 values	 of	 H1RO of loratadine 
(10	mg)	and	desloratadine	(5	mg)	in	this	study	with	those	from	pre‐
vious	 studies.	 As	 shown	 in	 Supporting	 Information	 Figure	 S2,	 the	
mean H1RO values of loratadine (10 mg) were very similar in the 
F I G U R E  5   Overall binding potential 
ratio	(BPR)	(left)	and	H1 receptor 




bars indicate means and standard 
deviations	(SD).	The	left	panel	shows	
the	BPRs	of	desloratadine	(squares),	





Bonferroni	P = 0.002). The right panel 
shows H1RO after oral administration of 
desloratadine	(squares)	and	loratadine	
(triangles):	mean	±	SD	6.47	±	10.5%	vs	
13.8	±	7.00%,	t test P = 0.103
ROI
Desloratadine Loratadine Placebo
Mean SD Mean SD Mean SD
FC 0.582 0.093 0.546*  0.086 0.630 0.075
TC 0.575 0.084 0.535*  0.086 0.603 0.076
OC 0.474 0.060 0.429*  0.059 0.508 0.033
PC 0.391 0.115 0.343*  0.089 0.425 0.097
ACG 0.607 0.108 0.588 0.113 0.649 0.082
PCG 0.648 0.138 0.582*  0.097 0.687 0.093





TA B L E  1  Binding	potential	ratio	based	
on region of interest




Mean SD Mean SD
FC 7.74 9.07 13.6 6.14
TC 4.29 11.5 11.2 9.24
OC 6.85 9.07 15.5 10.7
PC 9.18 12.0 19.6 10.0
ACG 6.56 10.7 9.69 10.7
PCG 5.54 15.1 15.4 4.88




aThere were no statistically significant differences between deslorata‐
dine and loratadine treatment. 
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present	and	previous	studies	(13.8%	vs	11.7%,	respectively),20 even 
though	 these	 studies	 were	 performed	 in	 different	 PET	 facilities.	
These data suggest the consistency and relevance of the classifica‐




a lower value than that in our study.20 These discrepancies could 
be	 explained	 by	 the	 following	 factors.	 First,	 our	 study	 recruited	
healthy	volunteers	as	participants,	whereas	 the	subjects	 in	Kubo's	
study were patients with moderate or severe chronic allergic rhinitis. 
Residual occupancy of antihistamines might have affected the lower 
BPR	in	patients.	Second,	the	two	studies	used	different	modalities	to	
acquire	PET	and	MRI	images.	Third,	the	two	studies	used	different	
methods	 of	 PET	 data	 analysis,	 such	 as	 definitions	 of	 the	 ROI	 and	
















































































































































































































































































































































































































F I G U R E  6  Relation	between	binding	potential	ratio	(BPR),	H1 
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The	BPR	of	desloratadine	was	similar	to	that	of	placebo,	whereas	
loratadine	had	a	significantly	lower	BPR	than	placebo	(Figure	4	and	
Table 1). These results indicate that loratadine might induce sleepi‐
ness caused by binding to brain cortical H1Rs. This is corroborated by 
the inverse relation between the plasma concentration of loratadine 
and	BPR	 (Figure	 6,	 upper	 panel,	 and	Table	 3).	 Furthermore,	H1RO 
after	loratadine	administration,	which	tended	to	be	proportional	to	
the	plasma	concentration	of	loratadine,	might	reinforce	the	binding	
property of loratadine to cortical H1R	(Figure	6,	lower	panel).	Severe	
subjective sleepiness was observed in some participants who re‐
ceived	 loratadine.	 Based	 on	 individual	 analyses,	 two	 participants	
who	 showed	 subjective	 sleepiness	 (+6.00	 and	 +4.00	 increase	 of	
SSS	 from	baseline)	 had	 relatively	 high	peak	plasma	 concentrations	
of	 loratadine	 (7.88	 and	 10.4	 ng	mL−1),	 low	BPR	 (0.448	 and	 0.423),	
and high H1RO	 (20.3%	 and	 14.8%)	 after	 oral	 administration	 of	 lo‐
ratadine	10	mg.	On	the	other	hand,	these	two	participants	exhibited	





data indicate that a clinical dose of loratadine can induce sleepiness 
due to high plasma concentrations and binding to brain H1Rs in some 
populations. The large variations in plasma concentration and H1RO 
may	be	related	to	genetic	variance	of	CYP3A56	and	P‐glycoprotein,57 




ing” antihistamine that could induce sedation or impaired perfor‐
mance when used at a higher than therapeutic dose.24,59‐61




loratadine (10 mg) showed similar time courses without significant 
differences	 between	 these	 treatments	 (Figure	 3).	 Fexofenadine,	
a	nonsedating	 second‐generation	antihistamine	and	an	active	me‐
tabolite	 of	 the	 prodrug	 terfenadine,	 also	 did	 not	 affect	 BPR	 after	
terfenadine administration.17,51 These results indicate that nonse‐
dating antihistamines converted from the absorbed prodrugs in vivo 
may	have	no	or	minimal	direct	effects	on	BPR.	In	general,	however,	
a	large	number	of	participants	in	[11C]‐doxepin‐PET	experiments	will	
be needed to demonstrate correlations of H1RO with plasma antihis‐




tential to cause significant sedation when compared with placebo. 
The failure to find significant differences may represent a type 2 
error	due	to	limited	sample	size	and	variability	among	participants.	A	
large number of participants are needed to demonstrate differences 
in	subjective	sleepiness	after	taking	nonsedating	antihistamines.
The limitations of this study include the large variations in H1RO 
of	desloratadine.	One	possible	explanation	 for	 this	 is	due	 to	 small	
number of participants and the simplified protocol used in this 
study.	We	did	 not	 perform	 continuous	PET	 scanning	 and	 simulta‐
neous arterial blood sampling to calculate the distribution volume 
of	 [11C]‐doxepin.	 Instead,	 we	 used	 the	 BPR,	 which	 may	 indicate	
[11C]‐doxepin	binding	 to	 regionally	 specific	H1R. This was done to 
relieve the participants from the burden of the long scanning time 
of	PET	and	sequential	arterial	blood	sampling.	Another	limitation	is	




affected the in vivo metabolism of administered drugs.56	 In	fact,	a	
participant	 who	 had	 low	 BPR	 and	 high	 H1RO from desloratadine 
treatment may have been affected by loratadine administration a 
week	previously	(Figure	5).
In	summary,	desloratadine	does	not	bind	significantly	to	H1R in 
the central nervous system and does not induce subjective sleep‐
iness at therapeutic doses. The H1RO	 of	 desloratadine	 5	mg	was	
6.47%,	which	was	 lower	than	that	of	 loratadine	 (13.8%).	These	re‐
sults	indicate	that	desloratadine	5	mg	does	not	penetrate	the	blood‐
brain barrier in large amounts enough to induce inhibition of H1R 
signaling resulting in sedation and cognitive impairment.
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